CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade RAPT Therapeutics, Inc. - RAPT CFD

8.93
0.56%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

RAPT Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 8.88
Open* 8.86
1-Year Change* -50.2%
Day's Range* 8.72 - 8.96
52 wk Range 10.47-31.45
Average Volume (10 days) 446.71K
Average Volume (3 months) 8.82M
Market Cap 808.66M
P/E Ratio -100.00K
Shares Outstanding 34.40M
Revenue N/A
EPS -2.88
Dividend (Yield %) N/A
Beta 0.52
Next Earnings Date Mar 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 8.93 0.13 1.48% 8.80 8.96 8.65
Mar 27, 2024 8.88 0.50 5.97% 8.38 8.97 8.32
Mar 26, 2024 8.37 0.19 2.32% 8.18 8.49 8.18
Mar 25, 2024 8.24 -0.07 -0.84% 8.31 8.52 8.18
Mar 22, 2024 8.32 -0.06 -0.72% 8.38 8.53 8.23
Mar 21, 2024 8.48 -0.20 -2.30% 8.68 9.04 8.46
Mar 20, 2024 8.65 0.26 3.10% 8.39 8.76 8.25
Mar 19, 2024 8.62 0.44 5.38% 8.18 8.66 8.09
Mar 18, 2024 8.32 -0.13 -1.54% 8.45 8.59 8.12
Mar 15, 2024 8.45 0.20 2.42% 8.25 8.69 8.25
Mar 14, 2024 8.39 -0.08 -0.94% 8.47 8.61 8.08
Mar 13, 2024 8.56 0.63 7.94% 7.93 8.69 7.78
Mar 12, 2024 7.93 -0.25 -3.06% 8.18 8.36 7.93
Mar 11, 2024 8.05 -1.01 -11.15% 9.06 9.06 7.98
Mar 8, 2024 9.06 -0.24 -2.58% 9.30 9.99 9.00
Mar 7, 2024 9.25 0.18 1.98% 9.07 9.57 9.00
Mar 6, 2024 9.13 0.45 5.18% 8.68 9.13 8.52
Mar 5, 2024 8.66 0.13 1.52% 8.53 8.80 8.44
Mar 4, 2024 8.65 -0.28 -3.14% 8.93 9.01 8.59
Mar 1, 2024 8.96 0.39 4.55% 8.57 9.24 8.50

RAPT Therapeutics, Inc. Events

Time (UTC) Country Event
Thursday, May 23, 2024

Time (UTC)

17:00

Country

US

Event

Rapt Therapeutics Inc Annual Shareholders Meeting
Rapt Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.527 3.813 5.042 0 0
Total Operating Expense 87.322 73.022 58.256 43.629 36.947
Selling/General/Admin. Expenses, Total 20.24 16.037 12.771 8.719 5.18
Research & Development 67.082 56.985 45.485 34.91 31.767
Operating Income -85.795 -69.209 -53.214 -43.629 -36.947
Other, Net 1.957 0.005 1.312 1.292 0.8
Net Income Before Taxes -83.838 -69.204 -51.902 -42.337 -36.147
Net Income After Taxes -83.838 -69.204 -52.892 -42.997 -36.147
Net Income Before Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Total Extraordinary Items
Net Income -83.838 -69.204 -52.892 -42.997 -36.147
Income Available to Common Excl. Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Income Available to Common Incl. Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Diluted Net Income -83.838 -69.204 -52.892 -42.997 -36.147
Diluted Weighted Average Shares 32.5404 27.3903 24.1343 22.7504 22.7504
Diluted EPS Excluding Extraordinary Items -2.57643 -2.52659 -2.19157 -1.88995 -1.58885
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.57643 -2.52659 -2.19157 -1.88995 -1.58885
Revenue 1.527 3.813 5.042
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0.886
Revenue 0 0 0 0 0.886
Total Operating Expense 28.364 31.562 24.431 21.678 19.795
Selling/General/Admin. Expenses, Total 6.722 5.988 4.977 5.079 5.436
Research & Development 21.642 25.574 19.454 16.599 14.359
Operating Income -28.364 -31.562 -24.431 -21.678 -18.909
Other, Net 3.084 2.291 1.48 0.443 -0.275
Net Income Before Taxes -25.28 -29.271 -22.951 -21.235 -19.184
Net Income After Taxes -25.28 -29.271 -22.951 -21.235 -19.184
Net Income Before Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Net Income -25.28 -29.271 -22.951 -21.235 -19.184
Income Available to Common Excl. Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Income Available to Common Incl. Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Diluted Net Income -25.28 -29.271 -22.951 -21.235 -19.184
Diluted Weighted Average Shares 38.3287 38.2805 35.7158 33.6843 31.1403
Diluted EPS Excluding Extraordinary Items -0.65956 -0.76464 -0.6426 -0.63041 -0.61605
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.65956 -0.76464 -0.6426 -0.63041 -0.61605
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 252.694 192.973 115.598 80.506 65.062
Cash and Short Term Investments 249.068 189.654 111.51 77.383 63.798
Cash & Equivalents 38.946 24.027 24.918 77.383 63.798
Prepaid Expenses 3.626 3.319 4.088 3.123 1.264
Total Assets 266.209 198.636 118.969 84.602 69.61
Property/Plant/Equipment, Total - Net 9.479 2.741 2.982 3.707 4.159
Property/Plant/Equipment, Total - Gross 17.728 10.425 10.064 9.766 9.128
Accumulated Depreciation, Total -8.249 -7.684 -7.082 -6.059 -4.969
Other Long Term Assets, Total 4.036 2.922 0.389 0.389 0.389
Total Current Liabilities 14.224 9.595 11.742 9.256 4.643
Accounts Payable 3.365 1.999 2.383 1.143 1.771
Accrued Expenses 10.827 6.326 4.935 3.642 2.488
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.032 1.27 4.424 4.471 0.384
Total Liabilities 21.043 12.256 14.79 11.481 5.612
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.819 2.661 3.048 2.225 0.969
Total Equity 245.166 186.38 104.179 73.121 63.998
Preferred Stock - Non Redeemable, Net 161.111
Common Stock 0.003 0.003 0.002 0.002 0.001
Additional Paid-In Capital 613.073 470.629 319.196 235.049 22.441
Retained Earnings (Accumulated Deficit) -367.884 -284.046 -214.842 -161.95 -118.953
Other Equity, Total -0.026 -0.206 -0.177 0.02 -0.602
Total Liabilities & Shareholders’ Equity 266.209 198.636 118.969 84.602 69.61
Total Common Shares Outstanding 34.2543 29.5551 24.7734 21.833 22.7504
Redeemable Preferred Stock 0 0 0 0
Short Term Investments 210.122 165.627 86.592
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 187.138 207.417 234.587 252.694 197.894
Cash and Short Term Investments 184.777 204.998 231.629 249.068 195.436
Cash & Equivalents 54.135 50.164 45.768 38.946 27.706
Short Term Investments 130.642 154.834 185.861 210.122 167.73
Prepaid Expenses 2.361 2.419 2.958 3.626 2.458
Total Assets 199.721 220.756 248.326 266.209 209.489
Property/Plant/Equipment, Total - Net 8.376 9.066 9.525 9.479 8.524
Property/Plant/Equipment, Total - Gross 17.442 17.807 18.073 17.728 16.531
Accumulated Depreciation, Total -9.066 -8.741 -8.548 -8.249 -8.007
Other Long Term Assets, Total 4.207 4.273 4.214 4.036 3.071
Total Current Liabilities 21.849 15.414 21.608 14.224 13.867
Accounts Payable 5.297 2.69 8.941 3.365 4.043
Accrued Expenses 16.499 12.628 12.626 10.827 9.791
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.053 0.096 0.041 0.032 0.033
Total Liabilities 26.921 21.079 27.856 21.043 20.183
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 5.072 5.665 6.248 6.819 6.316
Total Equity 172.8 199.677 220.47 245.166 189.306
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.003 0.003 0.003 0.003 0.003
Additional Paid-In Capital 626.724 622.289 617.283 613.073 534.689
Retained Earnings (Accumulated Deficit) -453.806 -422.435 -397.155 -367.884 -344.933
Other Equity, Total -0.121 -0.18 0.339 -0.026 -0.453
Total Liabilities & Shareholders’ Equity 199.721 220.756 248.326 266.209 209.489
Total Common Shares Outstanding 34.3604 34.3521 34.2897 34.2543 29.8862
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -83.838 -69.204 -52.892 -42.997 -36.147
Cash From Operating Activities -70.771 -61.026 -40.491 -35.474 -32.953
Cash From Operating Activities 1.047 0.996 1.123 1.33 1.237
Non-Cash Items 13.355 11.48 8.934 2.06 1.173
Changes in Working Capital -1.335 -4.298 2.344 4.133 0.784
Cash From Investing Activities -45.49 -81.347 -87.435 -0.843 -3.5
Capital Expenditures -0.845 -0.755 -0.398 -0.888 -3.5
Cash From Financing Activities 131.18 141.482 75.461 49.902 52.734
Issuance (Retirement) of Stock, Net 131.18 141.482 75.461 49.902 52.734
Net Change in Cash 14.919 -0.891 -52.465 13.585 16.281
Cash Taxes Paid 0 0.99 0.66
Other Investing Cash Flow Items, Total -44.645 -80.592 -87.037 0.045
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -29.271 -83.838 -60.887 -39.652 -20.468
Cash From Operating Activities -18.602 -70.771 -47.922 -30.773 -15.578
Cash From Operating Activities 0.299 1.047 0.795 0.535 0.261
Non-Cash Items 3.237 13.355 10.595 7.084 3.27
Changes in Working Capital 7.133 -1.335 1.575 1.26 1.359
Cash From Investing Activities 25.308 -45.49 -4.22 13.379 23.837
Capital Expenditures -0.759 -0.845 -0.796 -0.715 -0.149
Other Investing Cash Flow Items, Total 26.067 -44.645 -3.424 14.094 23.986
Cash From Financing Activities 0.116 131.18 55.821 50.57 0.132
Issuance (Retirement) of Stock, Net 0.116 131.18 55.821 50.57 0.132
Net Change in Cash 6.822 14.919 3.679 33.176 8.391

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

RAPT Therapeutics, Inc. Company profile

About Rapt Therapeutics Inc

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. FLX475 is in Phase I/II clinical trials. Its lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rapt Therapeutics Inc revenues decreased 24% to $3.8M. Net loss increased 31% to $69.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 27% to $51.7M (expense), General and administrative increase of 31% to $11.4M (expense).

Industry: Bio Therapeutic Drugs

561 Eccles Ave
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.63 Price
-1.420% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,543.77 Price
-0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

69,988.60 Price
-1.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading